Have a feature idea you'd love to see implemented?
Let us know!
ANIP Ani Pharmaceuticals Inc
Price (delayed)
$55.86
Market cap
$1.17B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
$1.66B
ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers),
Highlights
Ani Pharmaceuticals's revenue has increased by 24% YoY and by 3.1% from the previous quarter
The gross profit has grown by 17% year-on-year
Ani Pharmaceuticals's net income has shrunk by 153% YoY and by 126% QoQ
The company's EPS has shrunk by 147% QoQ
Key stats
What are the main financial stats of ANIP
Market
Valuations
Earnings
Shares outstanding
21.03M
Market cap
$1.17B
Enterprise value
$1.66B
Price to book (P/B)
2.9
Price to sales (P/S)
1.95
EV/EBIT
168.36
EV/EBITDA
23.09
EV/Sales
2.98
Revenue
$555.46M
EBIT
$9.83M
EBITDA
$71.67M
Free cash flow
$90.29M
Per share
Balance sheet
Liquidity
EPS
-$0.55
Free cash flow per share
$4.65
Book value per share
$19.29
Revenue per share
$28.63
TBVPS
$33.87
Total assets
$1.29B
Total liabilities
$856.58M
Debt
$625.36M
Equity
$405.95M
Working capital
$331.36M
Debt to equity
1.54
Current ratio
2.74
Quick ratio
1.84
Net debt/EBITDA
6.7
Margins
Efficiency
Dividend
EBITDA margin
12.9%
Gross margin
59.8%
Net margin
-1.3%
Operating margin
2.7%
Return on assets
-0.9%
Return on equity
-2%
Return on invested capital
1.4%
Return on capital employed
0.9%
Return on sales
1.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIP stock price
How has the Ani Pharmaceuticals stock price performed over time
Intraday
1.38%
1 week
-5.18%
1 month
-5.77%
1 year
7.82%
YTD
1.31%
QTD
-6.37%
Financial performance
How have Ani Pharmaceuticals's revenue and profit performed over time
Revenue
$555.46M
Gross profit
$332.11M
Operating income
$14.91M
Net income
-$7.09M
Gross margin
59.8%
Net margin
-1.3%
Ani Pharmaceuticals's net income has shrunk by 153% YoY and by 126% QoQ
The net margin has shrunk by 143% YoY and by 126% QoQ
ANIP's operating margin has dropped by 72% year-on-year and by 71% since the previous quarter
The company's operating income has shrunk by 70% QoQ and by 65% YoY
Growth
What is Ani Pharmaceuticals's growth rate over time
Valuation
What is Ani Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.9
P/S
1.95
EV/EBIT
168.36
EV/EBITDA
23.09
EV/Sales
2.98
The company's EPS has shrunk by 147% QoQ
The P/B is 24% above the 5-year quarterly average of 2.3 but 4.7% below the last 4 quarters average of 3.0
The company's equity fell by 11% QoQ and by 6% YoY
Ani Pharmaceuticals's revenue has increased by 24% YoY and by 3.1% from the previous quarter
The price to sales (P/S) is 17% lower than the last 4 quarters average of 2.3 and 13% lower than the 5-year quarterly average of 2.2
Efficiency
How efficient is Ani Pharmaceuticals business performance
The ROA has plunged by 164% YoY and by 132% from the previous quarter
The return on equity has dropped by 163% year-on-year and by 135% since the previous quarter
Ani Pharmaceuticals's ROIC has plunged by 85% from the previous quarter and by 80% YoY
The company's return on sales has shrunk by 83% QoQ and by 81% YoY
Dividends
What is ANIP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIP.
Financial health
How did Ani Pharmaceuticals financials performed over time
Ani Pharmaceuticals's total assets is 50% more than its total liabilities
ANIP's total liabilities has surged by 97% year-on-year and by 95% since the previous quarter
Ani Pharmaceuticals's total assets has increased by 45% YoY and by 40% from the previous quarter
The debt is 54% higher than the equity
The debt to equity has soared by 144% from the previous quarter and by 130% YoY
The debt has soared by 119% QoQ and by 119% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.